A Phase 1 interventional study of ORN252 in Healthy Volunteers - Male and Female, sponsored by Orna Therapeutics, Inc.. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by Orna Therapeutics, Inc. (part of Eli Lilly and Company) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the safety and tolerability of ORN252 in healthy adult participants.
This is the only study on the registry with Orna Therapeutics, Inc. as lead sponsor.
First submitted before Orna Therapeutics, Inc. became part of Eli Lilly and Company.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ascending single dose of ORN252 on a specified day
Biological: ORN252
ORN252 is a lipid nanoparticle encapsulating a circular RNA encoding an anti-CD19 CAR protein.
The incidence and severity of safety, clinical, and laboratory abnormalities in healthy adult participants.
To evaluate the safety and tolerability of ORN252 administered to healthy adult participants.
Time frame: 12 weeks
Pharmacokinetic (PK) parameters of ORN252 components
Area under the concentration versus time curve from time zero to the time of the last quantifiable concentration \[AUClast\]
Time frame: 29 days
Pharmacokinetic (PK) parameters of ORN252 components
Maximum concentration \[Cmax\]
Time frame: 29 days
Pharmacokinetic (PK) parameters of ORN252 components
Time of maximum concentration \[Tmax\]
Time frame: 29 days
Pharmacokinetic (PK) parameters of ORN252 components
Terminal elimination half-life \[t1/2\]
Time frame: 29 days
Pharmacokinetic (PK) parameters of ORN252 components
Volume of distribution \[Vdss\]
Time frame: 29 days
Pharmacokinetic (PK) parameters of ORN252 components
Clearance \[CL\]
Time frame: 29 days
Pharmacokinetic (PK) parameters of ORN252 components
Area under the concentration versus time curve from time zero to infinity (AUCinf)
Time frame: 29 days
Pharmacodynamic (PD) effects of of ORN252
Changes in circulating B cell counts and lymphocytes
Time frame: 12 weeks
Immunogenicity of ORN252
To assess the presence of anti-drug antibodies in healthy adult participants
Time frame: 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.